UNASSIGNED: A sub-group of @entity1 with @entity978 ( @entity978 ) who relapse after autologous stem cell transplant can achieve long-term disease-free-survival after allogeneic stem cell transplant (alloSCT). There is limited information regarding the tolerability and efficacy of double umbilical cord blood transplant (dUCBT) for relapsed/refractory @entity978 . We analyzed 27 consecutive, heavily pre-treated @entity1 receiving dUCBT for relapsed/refractory @entity978 at two centers from 2003-2014. The majority of @entity1 relapsed   <6 months after autologous stem cell transplant. A total of 15 @entity1 received myeloablative (most commonly melphalan, @entity3118 , thiotepa and anti-thymocyte globulin [ATG]) and 12 non-myeloablative conditioning regimens ( @entity3118 , @entity786 , 200cGy total body irradiation   +/- ATG). All @entity1 engrafted; median time to neutrophil and platelet engraftment was 17 and 37 days, respectively. Overall response rate was 68%; 58% achieved complete remission. Median progression-free survival (PFS) was 12.2 months; median overall survival was 27 months. Cumulative incidences of relapse and of non-relapse mortality at 5 years were 30% and 37.9%, respectively; 5-year PFS was 31.3% (95%CI 10.1-52.5). There was a trend toward inferior PFS in @entity1 with lymph node size   >= 2   cm at the time of alloSCT (p   =   0.07) and toward inferior survival in @entity1 with chemorefractory disease pre-alloSCT (p   =   0.12). dUCBT is feasible in @entity1 with heavily pre-treated @entity978 and can achieve long-term disease-free survival in approximately 30% of @entity1 .

Double umbilical cord blood transplant is effective therapy for relapsed or XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', 'Hodgkin Lymphoma'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']
@entity978 :: (MESH:D006689,Disease) :: ['refractory Hodgkin lymphoma']
